Clinical Trial Update: Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating pembrolizumab in combination with afatinib for non-small cell lung cancer with resistance to erlotinib; the study is completed and resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Jonathan Riess | Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer | Phase 1 | Status: COMPLETED | Results posted: 2024-10-16